0001140361-15-037232.txt : 20151008
0001140361-15-037232.hdr.sgml : 20151008
20151008174531
ACCESSION NUMBER: 0001140361-15-037232
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151006
FILED AS OF DATE: 20151008
DATE AS OF CHANGE: 20151008
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 151151578
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
4
1
doc1.xml
FORM 4
X0306
4
2015-10-06
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54, RUE LA BOETIE
PARIS
I0
75008
FRANCE
0
0
1
0
Common Stock
2015-10-06
4
P
0
1107
449.1383
A
23018099
I
See note
Common Stock
2015-10-06
4
P
0
1200
450.2306
A
23019299
I
See note
Common Stock
2015-10-06
4
P
0
1451
451.3084
A
23020750
I
See note
Common Stock
2015-10-06
4
P
0
1768
452.3727
A
23022518
I
See note
Common Stock
2015-10-06
4
P
0
3842
453.4794
A
23026360
I
See note
Common Stock
2015-10-06
4
P
0
4140
454.4757
A
23030500
I
See note
Common Stock
2015-10-06
4
P
0
3601
455.5580
A
23034101
I
See note
Common Stock
2015-10-06
4
P
0
2480
456.5556
A
23036581
I
See note
Common Stock
2015-10-06
4
P
0
2938
457.6022
A
23039519
I
See note
Common Stock
2015-10-06
4
P
0
9730
458.5797
A
23049249
I
See note
Common Stock
2015-10-06
4
P
0
6697
459.5495
A
23055946
I
See note
Common Stock
2015-10-06
4
P
0
12798
460.7054
A
23068744
I
See note
Common Stock
2015-10-06
4
P
0
9271
461.6131
A
23078015
I
See note
Common Stock
2015-10-06
4
P
0
5411
462.6074
A
23083426
I
See note
Common Stock
2015-10-06
4
P
0
5812
463.7103
A
23089238
I
See note
Common Stock
2015-10-06
4
P
0
1190
464.5745
A
23090428
I
See note
Common Stock
2015-10-06
4
P
0
900
466.0381
A
23091328
I
See note
Common Stock
2015-10-06
4
P
0
2200
467.3464
A
23093528
I
See note
Common Stock
2015-10-06
4
P
0
1702
468.4879
A
23095230
I
See note
Common Stock
2015-10-06
4
P
0
2300
469.4610
A
23097530
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
Purchase prices range from $448.70 to $449.50 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,297,978 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
Purchase prices range from $449.94 to $450.73 per share, inclusive.
Purchase prices range from $450.99 to $451.94 per share, inclusive.
Purchase prices range from $452.00 to $452.96 per share, inclusive.
Purchase prices range from $453.02 to $454.01 per share, inclusive.
Purchase prices range from $454.03 to $454.92 per share, inclusive.
Purchase prices range from $455.04 to $456.03 per share, inclusive.
Purchase prices range from $456.10 to $457.07 per share, inclusive.
Purchase prices range from $457.10 to $458.03 per share, inclusive.
Purchase prices range from $458.10 to $459.09 per share, inclusive.
Purchase prices range from $459.10 to $460.08 per share, inclusive.
Purchase prices range from $460.13 to $461.12 per share, inclusive.
Purchase prices range from $461.13 to $462.08 per share, inclusive.
Purchase prices range from $462.13 to $463.11 per share, inclusive.
Purchase prices range from $463.15 to $464.10 per share, inclusive.
Purchase prices range from $464.32 to $465.00 per share, inclusive.
Purchase prices range from $465.78 to $466.28 per share, inclusive.
Purchase prices range from $466.89 to $467.79 per share, inclusive.
Purchase prices range from $467.91 to $468.80 per share, inclusive.
Purchase prices range from $468.98 to $469.74 per share, inclusive.
Due to technical limitation of the number of transactions reported, this report is 1 of 2.
/s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law
2015-10-08